Protalix BioTherapeutics, Inc. (PLX) Financial Statements (2024 and earlier)

Company Profile

Business Address 2 UNIVERSITY PLAZA
HACKENSACK, NJ 07601
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17,11138,98518,26517,79237,80851,163
Cash and cash equivalents17,11138,98518,26517,79237,80851,163
Receivables4,5863,4422,0004,7004,7291,721
Inventory, net of allowances, customer advances and progress billings16,80417,95413,0828,1558,5697,833
Inventory16,80417,95413,0828,1558,5697,833
Other current assets1,3101,2852,0961,8321,8771,934
Other undisclosed current assets5,069 20,280   
Total current assets:44,88061,66655,72332,47952,98362,651
Noncurrent Assets
Operating lease, right-of-use asset5,0874,9605,5675,677
Property, plant and equipment4,5534,9624,8455,2736,3907,676
Deferred income tax assets    
Other undisclosed noncurrent assets1,2672,0771,7991,9631,7581,887
Total noncurrent assets:10,90711,99912,21112,9138,1489,563
TOTAL ASSETS:55,78773,66567,93445,39261,13172,214
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,27116,43313,92611,90510,2749,310
Accounts payable12,27116,43313,92611,90510,2749,310
Deferred revenue 13,1788,5505,39416,335
Debt  59,9335,440 5,921
Contract with customer, liability9,868
Other undisclosed current liabilities6,9808,1937,2216,4955,2117,521
Total current liabilities:32,42933,17686,47440,17525,35322,752
Noncurrent Liabilities
Long-term debt and lease obligation 28,18732,2634,46755,48547,96646,267
Long-term debt, excluding current maturities 28,18727,887 50,95747,96646,267
Liabilities, other than long-term debt5,81114,2624,03020,05440,69334,488
Deferred revenue and credits26,851
Deferred revenue  11,7901,71616,980
Contract with customer, liability33,027
Liability, pension and other postretirement and postemployment benefits1,6422,4722,2632,5652,3742,586
Other liabilities   515095,2925,051
Operating lease, liability4,1694,3764,4674,528
Total noncurrent liabilities:33,99846,5258,49775,53988,65980,755
Total liabilities:66,42779,70194,971115,714114,012103,507
Equity
Equity, attributable to parent(10,640)(6,036)(27,037)(70,322)(52,881)(31,293)
Common stock 54463515148144
Additional paid in capital 379,167368,852320,280270,492269,524266,495
Accumulated deficit (389,861)(374,934)(347,352)(340,829)(322,553)(297,932)
Other undisclosed equity, attributable to parent      
Total equity:(10,640)(6,036)(27,037)(70,322)(52,881)(31,293)
TOTAL LIABILITIES AND EQUITY:55,78773,66567,93445,39261,13172,214

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues47,63838,35062,89854,693 19,242
Cost of revenue(19,592)(16,349)(10,873)(10,895)(9,302)(15,231)
Gross profit:28,04622,00152,02543,798(9,302)4,011
Operating expenses(41,060)(42,463)(49,315)(54,592)(46,450)(43,700)
Other undisclosed operating income    7736,4443,336
Operating income (loss):(13,014)(20,462)2,710(10,717)(19,308)(36,353)
Nonoperating expense(1,383)(7,120)(9,233)(7,559)(7,149)(48,923)
Other nonoperating expense(1,383)(7,120)(9,233)(7,559)(7,149)(9,537)
Interest and debt expense  (831)(3,470)(2,991)(2,602)(2,334)
Income (loss) from continuing operations before income taxes:(14,397)(28,413)(9,993)(21,267)(29,059)(87,610)
Income tax expense(530)     
Other undisclosed loss from continuing operations      
Income (loss) from continuing operations:(14,927)(28,413)(9,993)(21,267)(29,059)(87,610)
Loss before gain (loss) on sale of properties:(28,413)(9,993)(21,267)(29,059)(87,610)
Net income (loss):(14,927)(28,413)(9,993)(21,267)(29,059)(87,610)
Other undisclosed net income attributable to parent  8313,4702,9912,6022,334
Net income (loss) available to common stockholders, basic:(14,927)(27,582)(6,523)(18,276)(26,457)(85,276)
Dilutive securities, effect on basic earnings per share      
Net income (loss) available to common stockholders, diluted:(14,927)(27,582)(6,523)(18,276)(26,457)(85,276)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(14,927)(28,413)(9,993)(21,267)(29,059)(87,610)
Comprehensive income (loss), net of tax, attributable to parent:(14,927)(28,413)(9,993)(21,267)(29,059)(87,610)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: